Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/20—Hypnotics; Sedatives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

• the present invention relates to new 1,2-benzisoxazole compounds and to pharmaceutical compositions containing them.
• the compounds of the present invention are 3-(piperid-4-yl)-1,2-benzisoxazole and 3-(piperazin-4-yl)-1,2-benzisoxazole compounds which are distinguished from the known compounds by their substituent in the 1-position of the piperidine or piperazine ring and by their pharmacological properties.
• various pharmacological tests carried out, both in vitro and in vivo have shown that the compounds of the invention are antagonists of 5HT 2A serotonin receptors, ⁇ 1 -adrenergic receptors and of dopaminergic receptors.
• the hyperactivity of the dopaminergic system is implicated not only in schizophrenia but in a large number of disorders of the central nervous system, such as anxiety or depressive disorders, impulsive disorders and aggressiveness.
• the products of the invention are thus more especially used as anti-psychotics, anxiolytics and anti-aggressives. They can also be used as antalgics.
• the present invention relates especially to the 1,2-benzisoxazole compounds of formula I ##STR2## wherein: A is selected from the group consisting of linear and branched alkyl having from 1 to 10 carbon atoms inclusive, unsubstituted phenyl, halophenyl, hydroxyphenyl and (lower alkoxy)phenyl,
• n is selected from zero and 1
• n is selected from 1 and 2
• E is selected from the group consisting of N and CH, and
• Y is selected from the group consisting of hydrogen, halogen, and alkoxy having from 1 to 5 carbon atoms inclusive,
• a and m are as defined hereinbefore and X is a halogen atom, in the presence of an alkali metal hydride, such as, for example, sodium hydride, in a polar solvent, such as, for example, dimethyl sulphoxide, to obtain the compounds of formula I; or
• the compounds of the present invention differ from the compounds of the prior art not only in their chemical structure but also in respect of their pharmacological and therapeutic activities. Those activities have been demonstrated:
• the present invention relates also to pharmaceutical compositions comprising as active ingredient a compound of formula I or a physiologically tolerable salt thereof, in mixture or association with one or more pharmaceutically appropriate excipients.
• compositions so obtained are generally in unit dose form containing from 0.5 to 25 mg of active ingredient. They may, for example, be in the form of tablets, dragees, gelatin capsules, suppositories or injectable or drinkable solutions, and may be administered by the oral, rectal or parenteral route.
• the dosage may vary according to the age and weight of the patient, the route of administration, the nature of the disorder and associated treatments, and ranges from 0.5 to 25 mg of active ingredient, from 1 to 3 times per day.
• Decanting is carried out, and the organic phase is washed several times with water and then extracted with a normal solution of hydrochloric acid.
• This product is prepared in the same manner as the compound of Example 1 but using 4-(6-fluoro-1,2-benzisoxazol-3-yl)piperazine instead of 4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidine in Step 1.
• the title compound so obtained melts at 125°-127° C.
• This product is prepared in the same manner as the compound of Example 1 but using 4-(6-fluoro-1,2-benzisoxazol-3-yl)piperazine instead of 4-(6-fluoro-1,2-benzisoxazol-3-yl)-piperidine in Step 1, and using bromoethane instead of 2-bromopropane in Step 2.
• the hydrochloride of the title compound so obtained melts at 201°-204° C.
• This product is prepared in the same manner as the compound of Example 1 but using 1-bromo-2-methylpropane instead of 2-bromopropane in Step 2.
• This product is obtained in the same manner as the compound of Example 5, but with replacement of the phenyl isocyanate by benzyl isocyanate in Step 1 of the synthesis.
• the expected product melts at 126°-130° C.
• This product is obtained in the same manner as the compound of Example 5, but with replacement of the phenyl isocyanate by 4-methoxyphenyl isocyanate in Step 1 of the synthesis.
• the expected product melts at 154°-157° C.
• This product is obtained in the same manner as the compound of Example 5, but with replacement of the phenyl isocyanate by 4-hydroxyphenyl isocyanate in Step 1 of the synthesis.
• the expected product melts at 190°-194° C.
• the separation of the radioligand that is bound to the receptors from the free radioligand is carried out by filtration through GF/B filters that have been pre-treated with 0.3% polyethyleneimine using a filtration apparatus of the Brandle Cell harvester type. Scintillation liquid is added to the filters, the radioactivity of which is counted using a beta-counter.
• the IC 50 concentration of the compound that inhibits the binding of the radioligand by 50%
• the products of the invention have K i values for the 5HT 2A and ⁇ 1 receptors that are less than 10 -8 M.
• the affinity for the D 4 receptor is generally 10 times greater than that for the D 2 receptor ( ⁇ 5 nM for D 4 vs. ⁇ 50 nM for D 2 )
• mice Test immediately after subcutaneous (s.c.) administration of the product or solvent (control group), the mouse is placed in a cylindrical cage (14 cm diam. ⁇ 14 cm height) with vertical bars. Thirty minutes later, the animal receives the dose of apomorphine (0.75 mg/kg, s.c.). The animals are observed 10 and 20 minutes after the injection of apomorphine and are given one of the following scores each time a measurement is taken: score 0 (four paws on the ground), score 1 (mouse upright, two front paws on the bars) or score 2 (mouse clinging by all four paws to the bars). The verticalisation score used for the results is from 0 to 4 (sum of the two scores). Each experimental group contains at least 5 animals.
• the ID 50 inhibitory dose is that dose of product which reduces by half the average of the verticalisation scores in comparison with the average of the control group.
• the product of Example 5 has an ID 50 in this test of 0.22 mg/kg.
• anti-psychotic products inhibit the conditioned Avoidance response at doses lower than those which inhibit the non-conditioned Escape response. That differentiates them from other classes of products (in particular, barbiturates and benzodiazepines), which inhibit both responses alike.
• the equipment consists of a cage divided into 2 compartments by a central partition; an opening in the partition allows the animal to move from one compartment to the other (LE 916 model, LETICA).
• the floor of each compartment is an electrified grid.
• the operation of the cage (light signal, passing of the electric current through the grid) and the recording of the movements of the animal from one compartment to the other are carried out by computer (COMPAQ 386S) using the software SHUTTLE 8 (LETICA).
• Test the animals are their own controls. Each daily session comprises 10 tests spaced at intervals of 30 seconds. A test consists of presenting the light signal (10 seconds), followed, or not, by the electric shock (0.460 mA, maximum duration 5 seconds) depending on the response of the animal to the light signal. The effects of a product on the avoidance responses are evaluated during a Test Session which takes places the day after a Control Session during the course of which the animals will have received the solvent. The product or the solvent is administered to the animal 30 minutes before the start of the Session. The parameter used is the number of avoidance responses.
• the average ID 50 inhibitory dose is that which reduces the number of conditioned avoidances by 50% compared with the control value.
• Results by way of example, the product of Example 5 administered subcutaneously has an ID 50 in this test of 0.88 mg/kg.
• This test allows the evaluation of the intraspecies anti-aggressive activity of a product in mice that have been kept in isolation for several months.
• mice Male CD mice (Charles River) weighing from 22 to 25 g on arrival at the animal house. Immediately on arrival the animals are isolated in individual cages made of opaque black polycarbonate (23 ⁇ 14 ⁇ 13 cm) having a grill lid, and are housed for a prolonged period (approximately 6 months) in the experimentation room.
• mice The selection of pairs of aggressive mice that will be used on a long-term basis in the study starts after the animals have been isolated for one month. Once or twice per week a mouse from another cage (intruder) is placed in the cage of a (resident) mouse and the two animals are observed to see if they attack one another (sniffing, pursuing, nipping, biting) during that trial. At the end of the trial (maximum duration of 10 minutes), each mouse is isolated again in its own cage. If attacks have occurred, the same pair will be tested again in the next trial; if there have been no attacks, each mouse of that pair will be placed in the presence of a different mouse in the following trial.
• Test takes place once a week. Thirty minutes before the two mice of the pair are placed together, each mouse receives the same treatment (product or solvent) and remains isolated in its respective cage. At TO minute, the intruder mouse is introduced into the cage of the resident mouse for a period of three minutes. The latent period (in seconds) before the first attack and the number and total duration (in seconds) of the attacks are observed. Any reversal of dominance of one mouse in relation to the other (generally the resident mouse is the dominant mouse) is also noted.
• the intruder mouse is returned to its cage; the animals remain in isolation until the next quick trial and test the following week.
• the ID 50 inhibitory dose of the number or duration of the attacks is that dose of product which reduces by half the average of each of those values compared with the average obtained, respectively, in the control group.
• Results by way of example, the product of Example 5 administered subcutaneously has an ID 50 in this test of 0.18 mg/kg.
• the catalepsy test comprises placing each rear paw of the animal on the front paw of the same side and measuring the time (seconds) during which the animal remains in that "crossed paws" position (maximum 30 seconds). Each animal is subjected to three successive tests (one every two minutes), the animal being removed from its cage and placed on the work surface. The tests are carried out one hour after the subcutaneous injection or oral administration of the product or its solvent. The average value of the three tests represents the duration of the catalepsy (in seconds) for each animal. There are five or six rats per experimental group.
• the average ED 50 effective dose of catalepsy induction is that dose which causes a catalepsy of a duration of 50% compared with the maximum value of 30 seconds (corrected by the value of the solvent control group).
• the product of Example 5 has an ED 50 in this test of 34 mg/kg, which compares very favourably with the reference compounds such as haloperidol or risperidone which in this test, administered subcutaneously, have an ED 50 of 0.15 mg/kg and 1.2 mg/kg, respectively.

Landscapes

• Organic Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Anesthesiology (AREA)
• Psychiatry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=9492694

Family Applications (1)

Country Status (19)

Cited By (25)

Families Citing this family (7)

Citations (4)

Family Cites Families (2)

• 1996
  • 1996-06-04 FR FR9606866A patent/FR2749304B1/fr not_active Expired - Lifetime
• 1997
  • 1997-05-28 JP JP9138264A patent/JPH1059967A/ja not_active Withdrawn
  • 1997-06-02 NO NO972510A patent/NO308360B1/no not_active IP Right Cessation
  • 1997-06-02 AU AU24649/97A patent/AU715266B2/en not_active Ceased
  • 1997-06-03 CN CN97105471A patent/CN1073565C/zh not_active Expired - Fee Related
  • 1997-06-03 US US08/868,116 patent/US5780474A/en not_active Expired - Fee Related
  • 1997-06-03 NZ NZ314992A patent/NZ314992A/xx unknown
  • 1997-06-03 HU HU9700992A patent/HUP9700992A3/hu unknown
  • 1997-06-03 CA CA002207835A patent/CA2207835C/fr not_active Expired - Fee Related
  • 1997-06-03 PL PL97320325A patent/PL187005B1/pl not_active IP Right Cessation
  • 1997-06-04 PT PT97401243T patent/PT811622E/pt unknown
  • 1997-06-04 ES ES97401243T patent/ES2148916T3/es not_active Expired - Lifetime
  • 1997-06-04 EP EP97401243A patent/EP0811622B1/fr not_active Expired - Lifetime
  • 1997-06-04 DK DK97401243T patent/DK0811622T3/da active
  • 1997-06-04 AT AT97401243T patent/ATE192745T1/de not_active IP Right Cessation
  • 1997-06-04 DE DE69701923T patent/DE69701923T2/de not_active Expired - Fee Related
  • 1997-06-04 BR BR9703447A patent/BR9703447A/pt not_active IP Right Cessation
  • 1997-06-04 ZA ZA9704919A patent/ZA974919B/xx unknown
• 2000
  • 2000-07-21 GR GR20000401682T patent/GR3033996T3/el not_active IP Right Cessation

Patent Citations (4)

Also Published As

Similar Documents

Legal Events